Genspera Inc (GNSZ) 0.3400 $GNSZ
GenSpera Inc. - "'Precision Medicine' and Biomarkers"
ACCESSWIRE - Fri Sep 18, 10:16AM CDT
NEW YORK, NY / ACCESWIRE / September 18, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Due Diligence Provides Insight into GenSpera's Sharp Drop in Valuation
ACCESSWIRE - Thu Sep 10, 7:35AM CDT
NEW YORK, NY / ACCESSWIRE / September 10, 2015 / GenSpera, Inc. (OTCQB: GNSZ) shares fell 27.78% or $.25 to close at $.65 per share in Wednesdays session. Trading volume exceeded the 30 day average by a factor of thirteen.
GenSpera Inc. - "Winning the Name Game"
ACCESSWIRE - Thu Sep 10, 7:19AM CDT
NEW YORK, NY / ACCESSWIRE / September 10, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors
Marketwired - Wed Sep 09, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today announced that interim data from its Phase II study of mipsagargin (G-202) in adult patients with recurrent or progressive glioblastoma has demonstrated impressive activity in patients to date. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, CA.
GenSpera to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Marketwired - Mon Aug 24, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, will present at Rodman & Renshaw's 17th Annual Global Investment Conference on Wednesday, September 9, 2015 from 10:50 to 11:15 AM in Library (2nd floor), St. Regis Hotel, New York City.
Metastatic Hormone Refractory Prostate Cancer Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Mon Aug 17, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffhfkg/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects Companies Mentioned - AB Science - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - CellCentric Ltd - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncogenex Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ffhfkg/metastatic
ARWR: 5.89 (+0.13), AMBX: (), ADMP: 4.00 (-0.05), MDVN: 41.26 (+2.03), JNJ: 95.37 (+0.29), NLNK: 34.31 (+1.42), ABBV: 55.64 (-0.40), ADXS: 11.07 (+0.83), ONCY: 0.45 (unch), EBS: 30.49 (+0.77), AMGN: 149.59 (-0.31), BIND: 4.52 (+0.03), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), GTXI: 0.96 (unch), BLCM: 14.65 (+0.39), AZN: 32.23 (-0.16), CELGZ: 1.74 (+0.04), KPTI: 11.75 (+0.04), NVS: 91.90 (-0.71)
GenSpera Provides 2nd Quarter Corporate Update
Marketwired - Mon Aug 10, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) on August 6, 2015, the company reported its financial results for the three and six months ended June 31, 2015, and has provided the following corporate update to its shareholders in order to highlight the Company's extensive organizational advances and clinical progress during the second quarter of 2015. GenSpera continues to unlock conventional thinking to conceive, design, and develop novel cancer therapies. GenSpera's unique technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides targeted release of drug candidates within tumors.
Renal Cell Carcinoma Pipeline Review, H1 2015 - 81 Companies & 130 Drug Profiles
M2 - Fri Jul 31, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjmhc/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Angiogene Pharmaceuticals Limited - arGEN-X BV - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Biogenomics Limited - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Conkwest, Inc. - CureTech Ltd. - Cytune Pharma SAS - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genor BioPharma Co., Ltd. - GenSpera, Inc. - GlaxoSmithKline Plc For more information visit http://www.researchandmarkets.com/research/cmjmhc/renal_cell
CERU: 3.65 (+0.07), AMBX: (), CLDX: 12.80 (+1.06), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), AMPE: 3.04 (+0.05), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CLBS: 1.38 (unch), ARGS: 5.80 (-0.18), NK: 13.09 (-0.21), CALA: 7.61 (+0.09), EXEL: 5.99 (+0.14), XLRN: 24.08 (-0.18)
GenSpera Inc. - "Why Partner: The Partnering Process - Part Two"
ACCESSWIRE - Thu Jul 30, 7:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 30, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Inc. - "Why Partner - Part One"
ACCESSWIRE - Wed Jul 29, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 29, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting
Marketwired - Tue Jul 28, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that the Society for Neuro-Oncology and the 2015 Scientific Program Committee has accepted an abstract for presentation at the Society for Neuro-Oncology's 20th Annual Scientific Meeting. The abstract is titled: "Phase II study of mipsagargin (G-202), a PSMA-activated prodrug targeting the tumor endothelium, in adult patients with recurrent or progressive glioblastoma," and will be presented during the annual meeting in San Antonio, Texas, between November 19-22, 2015. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, CA, and will evaluate the efficacy, safety and central nervous system (CNS) exposure in patients with recurrent or progressive glioblastoma.
U.S. Court of Appeals Enters Judgment in Favor of GenSpera
Marketwired - Mon Jul 20, 7:01AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today the U.S. Court of Appeals for the Federal Circuit found in favor of GenSpera.
GenSpera Inc. - "Expanded Intellectual Property for Thapsigargin Production"
ACCESSWIRE - Tue Jul 14, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 14, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)
Marketwired - Mon Jul 13, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today announced that its strategic partner Phyton Biotech, the pioneer in Plant Cell Fermentation (PCF(R)), has had its international patent application WO 2015/0892978 A1 "PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE," published by the World Intellectual Property Organization (WIPO).
GenSpera Announces Private Placement of $2.5 Million
Marketwired - Mon Jul 06, 8:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that it has entered into definitive agreements with institutional investors, led by a healthcare dedicated fund, for the private placement of shares of common stock and warrants to purchase shares of common stock for gross proceeds of $2.5 million.
GenSpera Inc. - "Pricing vs Value of Cancer Drugs"
ACCESSWIRE - Wed Jul 01, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
U.S. Food and Drug Administration's Office of Orphan Products Development Issues Grant Supporting GenSperas Glioblastoma Study
Marketwired - Wed Jun 17, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Santosh Kesari, MD, PhD, Principal Investigator of GenSpera's glioblastoma clinical trial, received an RO-1 grant from the Food and Drug Administration for ongoing mipsagargin clinical trial studies in humans. The clinical trial is being conducted at UC San Diego Moores Cancer Center in La Jolla, CA.
Craig A. Dionne to Speak at BIO International 2015
Marketwired - Mon Jun 15, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, will present at BIO International Convention 2015 on Wednesday, June 17, 2015 at 2:00 P.M. in Philadelphia, PA.
Recurrent Glioblastoma Multiforme (GBM) Pipeline Review, H1 2015
M2 - Thu Jun 11, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht3nzs/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agenus, Inc. - Amgen Inc. - AngioChem Inc. - Apogenix GmbH - AstraZeneca PLC - Axelar AB - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Celldex Therapeutics, Inc. - e-Therapeutics plc - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - ERC Belgium SA - GenSpera, Inc. - GlaxoSmithKline plc - GW Pharmaceuticals plc - ImmunoCellular Therapeutics, Ltd. - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Novartis AG - OncoEthix SA - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Sangamo BioSciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Tocagen Inc. - Vascular Biogenics Ltd. - Virttu Biologics Limited - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/ht3nzs/recurrent
ZIOP: 10.92 (+0.32), PFE: 33.24 (+0.15), CLDX: 12.80 (+1.06), SGMO: 5.94 (+0.38), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), IMUC: 0.44 (-0.01), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), VBLT: 7.35 (-0.23), KPTI: 11.75 (+0.04), NVS: 91.90 (-0.71)
GenSpera And Cancer-Specific Hand Grenades
Jason Napodano, CFA - at Seeking Alpha - Wed Jun 10, 6:52AM CDT
GenSpera Inc. - "'Precision Medicine' and Biomarkers"
ACCESSWIRE - Fri Sep 18, 10:16AM CDT
NEW YORK, NY / ACCESWIRE / September 18, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Due Diligence Provides Insight into GenSpera's Sharp Drop in Valuation
ACCESSWIRE - Thu Sep 10, 7:35AM CDT
NEW YORK, NY / ACCESSWIRE / September 10, 2015 / GenSpera, Inc. (OTCQB: GNSZ) shares fell 27.78% or $.25 to close at $.65 per share in Wednesdays session. Trading volume exceeded the 30 day average by a factor of thirteen.
GenSpera Inc. - "Winning the Name Game"
ACCESSWIRE - Thu Sep 10, 7:19AM CDT
NEW YORK, NY / ACCESSWIRE / September 10, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors
Marketwired - Wed Sep 09, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today announced that interim data from its Phase II study of mipsagargin (G-202) in adult patients with recurrent or progressive glioblastoma has demonstrated impressive activity in patients to date. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, CA.
GenSpera to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Marketwired - Mon Aug 24, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, will present at Rodman & Renshaw's 17th Annual Global Investment Conference on Wednesday, September 9, 2015 from 10:50 to 11:15 AM in Library (2nd floor), St. Regis Hotel, New York City.
Metastatic Hormone Refractory Prostate Cancer Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Mon Aug 17, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffhfkg/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects Companies Mentioned - AB Science - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - CellCentric Ltd - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncogenex Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ffhfkg/metastatic
ARWR: 5.89 (+0.13), AMBX: (), ADMP: 4.00 (-0.05), MDVN: 41.26 (+2.03), JNJ: 95.37 (+0.29), NLNK: 34.31 (+1.42), ABBV: 55.64 (-0.40), ADXS: 11.07 (+0.83), ONCY: 0.45 (unch), EBS: 30.49 (+0.77), AMGN: 149.59 (-0.31), BIND: 4.52 (+0.03), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), GTXI: 0.96 (unch), BLCM: 14.65 (+0.39), AZN: 32.23 (-0.16), CELGZ: 1.74 (+0.04), KPTI: 11.75 (+0.04), NVS: 91.90 (-0.71)
GenSpera Provides 2nd Quarter Corporate Update
Marketwired - Mon Aug 10, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) on August 6, 2015, the company reported its financial results for the three and six months ended June 31, 2015, and has provided the following corporate update to its shareholders in order to highlight the Company's extensive organizational advances and clinical progress during the second quarter of 2015. GenSpera continues to unlock conventional thinking to conceive, design, and develop novel cancer therapies. GenSpera's unique technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides targeted release of drug candidates within tumors.
Renal Cell Carcinoma Pipeline Review, H1 2015 - 81 Companies & 130 Drug Profiles
M2 - Fri Jul 31, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjmhc/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Angiogene Pharmaceuticals Limited - arGEN-X BV - Argos Therapeutics, Inc. - Astellas Pharma Inc. - Bayer AG - Beta Pharma, Inc. - Bio-Cancer Treatment International Limited - Biogenomics Limited - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Calithera Biosciences, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Conkwest, Inc. - CureTech Ltd. - Cytune Pharma SAS - Eisai Co., Ltd. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genor BioPharma Co., Ltd. - GenSpera, Inc. - GlaxoSmithKline Plc For more information visit http://www.researchandmarkets.com/research/cmjmhc/renal_cell
CERU: 3.65 (+0.07), AMBX: (), CLDX: 12.80 (+1.06), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), AMPE: 3.04 (+0.05), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CLBS: 1.38 (unch), ARGS: 5.80 (-0.18), NK: 13.09 (-0.21), CALA: 7.61 (+0.09), EXEL: 5.99 (+0.14), XLRN: 24.08 (-0.18)
GenSpera Inc. - "Why Partner: The Partnering Process - Part Two"
ACCESSWIRE - Thu Jul 30, 7:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 30, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Inc. - "Why Partner - Part One"
ACCESSWIRE - Wed Jul 29, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 29, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
GenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting
Marketwired - Tue Jul 28, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that the Society for Neuro-Oncology and the 2015 Scientific Program Committee has accepted an abstract for presentation at the Society for Neuro-Oncology's 20th Annual Scientific Meeting. The abstract is titled: "Phase II study of mipsagargin (G-202), a PSMA-activated prodrug targeting the tumor endothelium, in adult patients with recurrent or progressive glioblastoma," and will be presented during the annual meeting in San Antonio, Texas, between November 19-22, 2015. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, CA, and will evaluate the efficacy, safety and central nervous system (CNS) exposure in patients with recurrent or progressive glioblastoma.
U.S. Court of Appeals Enters Judgment in Favor of GenSpera
Marketwired - Mon Jul 20, 7:01AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today the U.S. Court of Appeals for the Federal Circuit found in favor of GenSpera.
GenSpera Inc. - "Expanded Intellectual Property for Thapsigargin Production"
ACCESSWIRE - Tue Jul 14, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 14, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)
Marketwired - Mon Jul 13, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) today announced that its strategic partner Phyton Biotech, the pioneer in Plant Cell Fermentation (PCF(R)), has had its international patent application WO 2015/0892978 A1 "PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE," published by the World Intellectual Property Organization (WIPO).
GenSpera Announces Private Placement of $2.5 Million
Marketwired - Mon Jul 06, 8:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that it has entered into definitive agreements with institutional investors, led by a healthcare dedicated fund, for the private placement of shares of common stock and warrants to purchase shares of common stock for gross proceeds of $2.5 million.
GenSpera Inc. - "Pricing vs Value of Cancer Drugs"
ACCESSWIRE - Wed Jul 01, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
U.S. Food and Drug Administration's Office of Orphan Products Development Issues Grant Supporting GenSperas Glioblastoma Study
Marketwired - Wed Jun 17, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Santosh Kesari, MD, PhD, Principal Investigator of GenSpera's glioblastoma clinical trial, received an RO-1 grant from the Food and Drug Administration for ongoing mipsagargin clinical trial studies in humans. The clinical trial is being conducted at UC San Diego Moores Cancer Center in La Jolla, CA.
Craig A. Dionne to Speak at BIO International 2015
Marketwired - Mon Jun 15, 7:30AM CDT
GenSpera, Inc. (OTCQB: GNSZ) announced today that Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, will present at BIO International Convention 2015 on Wednesday, June 17, 2015 at 2:00 P.M. in Philadelphia, PA.
Recurrent Glioblastoma Multiforme (GBM) Pipeline Review, H1 2015
M2 - Thu Jun 11, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht3nzs/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agenus, Inc. - Amgen Inc. - AngioChem Inc. - Apogenix GmbH - AstraZeneca PLC - Axelar AB - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Celldex Therapeutics, Inc. - e-Therapeutics plc - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - ERC Belgium SA - GenSpera, Inc. - GlaxoSmithKline plc - GW Pharmaceuticals plc - ImmunoCellular Therapeutics, Ltd. - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Novartis AG - OncoEthix SA - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Sangamo BioSciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Tocagen Inc. - Vascular Biogenics Ltd. - Virttu Biologics Limited - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/ht3nzs/recurrent
ZIOP: 10.92 (+0.32), PFE: 33.24 (+0.15), CLDX: 12.80 (+1.06), SGMO: 5.94 (+0.38), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), IMUC: 0.44 (-0.01), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), VBLT: 7.35 (-0.23), KPTI: 11.75 (+0.04), NVS: 91.90 (-0.71)
GenSpera And Cancer-Specific Hand Grenades
Jason Napodano, CFA - at Seeking Alpha - Wed Jun 10, 6:52AM CDT
